Synthesis of curcumin derivatives for suppression of castration-resistant prostate cancer

被引:2
|
作者
Gong, Shunze [1 ,4 ]
Yuan, Chixiang [1 ]
Hu, Hang [2 ,3 ,5 ]
Xu, Defeng [2 ,3 ,5 ]
机构
[1] Taizhou Vocat & Tech Coll, Taizhou, Peoples R China
[2] Changzhou Univ, Sch Pharm, Changzhou, Peoples R China
[3] Jiangsu Hope Pharm Co Ltd, Changzhou, Peoples R China
[4] Taizhou Vocat & Tech Coll, Taizhou 318000, Peoples R China
[5] Changzhou Univ, Sch Pharm, Changzhou 213164, Peoples R China
关键词
androgen receptor; castration-resistant prostate cancer; curcumin derivatives; dimethylcurcumin; inhibitory activity; ANDROGEN DEPRIVATION THERAPY; DIMETHYLCURCUMIN; DEGRADATION;
D O I
10.1177/17475198241230042
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
In this work, 20 curcumin derivatives containing halogen atoms or nitrogen atoms were synthesized for suppression of castration-resistant prostate cancer. These curcumin derivatives were prepared by aldol condensation between the substituted benzaldehydes and acetylacetone or ethyl 3-acetyl-4-oxopentanoate. All synthesized compounds were characterized by 1H nuclear magnetic resonance, 13C nuclear magnetic resonance, high resolution mass, ultraviolet-visible spectroscopy, fluorescence spectroscopy, and high-performance liquid chromatography. The in vitro cytotoxicity of the prepared compounds against 22Rv1 cells was evaluated by the standard MTT assay. The compounds with good inhibitory activity against 22Rv1 cells were further tested for androgen receptor suppression effect. The results show that all compounds were successfully prepared and the purities are all over 90%. Among all synthesized compounds, compound p and s exhibit better inhibitory activity against 22Rv1 cells as compared to dimethylcurcumin, compound q and r display similar inhibitory activity against 22Rv1 cells as compared to dimethylcurcumin. Compounds p-s also demonstrate enhanced androgen receptor suppression effect against 22Rv1 cells as compared to dimethylcurcumin. This work indicates that compounds p-s show promising inhibitory activity against castration-resistant prostate cancer cells by suppression of androgen receptor.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Olaparib for Metastatic Castration-Resistant Prostate Cancer
    de Bono, J.
    Mateo, J.
    Fizazi, K.
    Saad, F.
    Shore, N.
    Sandhu, S.
    Chi, K. N.
    Sartor, O.
    Agarwal, N.
    Olmos, D.
    Thiery-Vuillemin, A.
    Twardowski, P.
    Mehra, N.
    Goessl, C.
    Kang, J.
    Burgents, J.
    Wu, W.
    Kohlmann, A.
    Adelman, C. A.
    Hussain, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22): : 2091 - 2102
  • [32] Advances in metastatic castration-resistant prostate cancer
    Kentepozidis, Nikolaos
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S108 - S108
  • [33] Predicting the future in castration-resistant prostate cancer
    Verhagen, Paul
    LANCET ONCOLOGY, 2009, 10 (03): : 201 - 202
  • [34] Cabazitaxel for the treatment of castration-resistant prostate cancer
    Agarwal, Neeraj
    Sonpavde, Guru
    Sartor, Oliver
    FUTURE ONCOLOGY, 2011, 7 (01) : 15 - 24
  • [35] Novel treatments for castration-resistant prostate cancer
    Sternberg, Cora N.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S195 - S199
  • [36] Visceral Disease in Castration-resistant Prostate Cancer
    Pezaro, Carmel J.
    Omlin, Aurelius
    Lorente, David
    Rodrigues, Daniel Nava
    Ferraldeschi, Roberta
    Bianchini, Diletta
    Mukherji, Deborah
    Riisnaes, Ruth
    Altavilla, Amelia
    Crespo, Mateus
    Tunariu, Nina
    de Bono, Johann S.
    Attard, Gerhardt
    EUROPEAN UROLOGY, 2014, 65 (02) : 270 - 273
  • [37] Pathophysiology and therapy of castration-resistant prostate cancer
    Merseburger, A. S.
    Kuczyk, M. A.
    Wolff, J. M.
    UROLOGE, 2013, 52 (02): : 219 - 225
  • [38] Castration-resistant Prostate cancer: Treatment is differentiated
    Wolff, Johannes M.
    AKTUELLE UROLOGIE, 2011, 42 (02)
  • [39] Current State of Castration-Resistant Prostate Cancer
    Petrylak, Daniel P.
    AMERICAN JOURNAL OF MANAGED CARE, 2013, 19 (18): : S358 - S365
  • [40] Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
    Fizazi, Karim
    Shore, Neal
    Tammela, Teuvo L.
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris
    Kuss, Iris
    Kappeler, Christian
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (13): : 1235 - 1246